Gilead completes Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
Study Meets Primary Endpoint of Non-inferiority
27-Feb-2007 -
Gilead Sciences, Inc. announced the completion of a Phase II clinical trial of GS 9137, a novel oral HIV integrase inhibitor. The clinical study met its primary endpoint of non-inferiority in viral load reduction in HIV-positive patients receiving 50 mg or 125 mg of GS 9137 once daily, each ...
clinical trials
GILEAD Sciences
HIV
+4